Vikas Sinha, Chief Financial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 10,410 shares of the company's common stock on April 16, 2026, at a price of $49.5745 per share. The transaction generated gross proceeds of approximately $516,070. The sale took place while the share price was trading close to its 52-week high of $51.62, a level that represents roughly a 55% gain for the stock over the past 12 months.
The filing indicates the sale was a "sell to cover" transaction made to satisfy tax withholding obligations tied to restricted stock units (RSUs) that vested on April 15, 2026. Scholar Rock's equity incentive plans require that the tax obligation be funded through a brokerage firm designated by the issuer, and the disclosure explicitly states that the sale was not a discretionary trade by Mr. Sinha.
The vested shares originated from awards granted on April 27, 2025. Those awards vest on an annual schedule over four years and are contingent on continued service. Following the April 16 transaction, Mr. Sinha's reported holdings in Scholar Rock total 619,856 shares of common stock. That aggregate comprises 47,835 shares of common stock currently held, 122,021 RSUs subject to time-based vesting conditions, and 450,000 RSUs that are subject to both performance- and time-based vesting conditions.
Market commentary cited in the filing references InvestingPro analysis, which characterizes the stock as appearing overvalued at current levels. Analyst price targets for Scholar Rock span a range from $48 to $70. The filing notes that a detailed Pro Research Report with further valuation analysis is available through InvestingPro.
In parallel to the insider transaction, Scholar Rock has resubmitted its Biologics License Application (BLA) for apitegromab to the U.S. Food and Drug Administration. The resubmission includes information for Catalent Indiana LLC - now part of Novo Nordisk - and a second U.S.-based fill-finish facility. The company pursued the resubmission following a Type C meeting with the FDA intended to address items identified in a prior Complete Response Letter related to facility observations.
Analysts have reacted to these regulatory developments with upward target adjustments while maintaining positive coverage. Jefferies increased its price target to $57 and BofA Securities moved its target to $58, each keeping a Buy rating. Truist Securities reiterated a Buy rating with a $55 price target after Roche halted development of a competing therapy. Scholar Rock anticipates a PDUFA date in late September 2026 for its apitegromab filing.
These actions - the sell-to-cover trade by the company's CFO and the regulatory resubmission for apitegromab - were detailed in the company's filings and in analyst commentary. The disclosure surrounding the insider sale describes a required tax-withholding mechanism tied to RSU vesting and clarifies that the transaction was not a discretionary sale by the executive.